P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
JournalLeukemia Research
Volume33
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2009

Cite this